DexComDXCM
Market Cap: $27.3B
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
44% more repeat investments, than reductions
Existing positions increased: 430 | Existing positions reduced: 299
2% less call options, than puts
Call options by funds: $517M | Put options by funds: $526M
1.45% less ownership
Funds ownership: 95.28% [Q1] → 93.83% (-1.45%) [Q2]
3% less funds holding
Funds holding: 1,004 [Q1] → 969 (-35) [Q2]
17% less capital invested
Capital invested by funds: $50.9B [Q1] → $42.3B (-$8.61B) [Q2]
24% less first-time investments, than exits
New positions opened: 109 | Existing positions closed: 144
42% less funds holding in top 10
Funds holding in top 10: 24 [Q1] → 14 (-10) [Q2]
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Piper Sandler Matt O'Brien 50% 1-year accuracy 22 / 44 met price target | 31%upside $90 | Overweight Reiterated | 26 Aug 2024 |
Stifel Mathew Blackman 44% 1-year accuracy 7 / 16 met price target | 46%upside $100 | Buy Maintained | 23 Aug 2024 |
Baird Jeff Johnson 58% 1-year accuracy 7 / 12 met price target | 20%upside $82 | Neutral Maintained | 5 Aug 2024 |
Barclays Matt Miksic 59% 1-year accuracy 17 / 29 met price target | 65%upside $113 | Equal-Weight Maintained | 29 Jul 2024 |
BTIG Marie Thibault 86% 1-year accuracy 6 / 7 met price target | 75%upside $120 | Buy Maintained | 26 Jul 2024 |
Financial journalist opinion
Based on 335 articles about DXCM published over the past 30 days